Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myelodysplastic syndrome.

Ghulam Mufti1, Alan F List, Steven D Gore

  • 1Kings College Hospital, Department of Haematology, London, UK.

Hematology. American Society of Hematology. Education Program
|November 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

JCO precision oncology·2026
Same author

Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag.

NEJM evidence·2026
Same author

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.

American journal of hematology·2026
Same author

A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).

Cancer·2026
Same author

Exposure to Agent Orange and association with myelodysplastic syndromes.

Blood advances·2026
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Novel therapies are emerging for myelodysplastic syndromes (MDS), moving beyond supportive care. Research highlights targeted treatments, including immunomodulatory drugs, DNA methylation inhibitors, and bone marrow transplantation, offering new hope for MDS patients.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and risk of leukemic transformation.
  • Classifications like WHO and IPSS aid in defining MDS subgroups with distinct abnormalities.
  • Historically, MDS treatment relied on supportive care, primarily transfusions.

Purpose of the Study:

  • To review recent advancements in MDS therapeutic strategies.
  • To highlight novel treatments targeting molecular mechanisms and clinical trials.
  • To provide an update on bone marrow transplantation and immunomodulatory approaches.

Main Methods:

  • Review of therapeutic strategies focusing on apoptosis and targeted small molecules.
  • Analysis of clinical trial results for DNA methylation inhibitors (5-azacytidine, Decitabine).

Related Experiment Videos

  • Examination of bone marrow transplantation outcomes, including reduced-intensity conditioning and immune modulation.

    • Main Results:

    • Emerging targeted therapies include immunomodulatory drugs (IMiDs), VEGF receptor inhibitors, arsenic trioxide, and others.
    • DNA methylation inhibitors (5-AC, Decitabine) show promise, with combination therapies (HDAC and DNA methyltransferase inhibitors) under investigation.
    • Reduced-intensity bone marrow transplants offer graft-versus-leukemia effects with reduced early mortality.

    Conclusions:

    • Novel therapeutic strategies are significantly advancing MDS treatment.
    • Targeted therapies and innovative transplantation methods offer improved outcomes for MDS patients.
    • Continued research into molecular mechanisms and combination therapies is crucial for further progress.